Strata Skin Sciences Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 7.07, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Strata Skin Sciences Inc in Dec 31 2025 quarter, has decreased to 52 days, compared to 55 days, in the Sep 30 2025 quarter.

If we take a look into Healthcare sector 218 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from 958 to 2005.

What is Receivable Turnover Ratio?
What is Strata Skin Sciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SSKN Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	-21.55 %	-21.13 %	1.08 %	37.93 %	18.31 %
Y / Y Revenue Change	-2.97 %	-25.56 %	-7.95 %	9.33 %	10.21 %
Receivable Turnover Ratio (TTM)	7.07	6.68	6.8	6.95	7.37
SSKN's Total Ranking	# 2005	# 958	# 929	# 1277	# 1085
Accounts Receivable average collection period days	52	55	54	53	50
Seq. Receivable Change	17.61 %	-12.88 %	-19.67 %	-4.68 %	18.23 %
Seq. Revenue Change	50.26 %	-15.36 %	9.91 %	-30.59 %	15.28 %

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 76
Healthcare Sector	# 219
Overall Market	# 2005

Receivable Turnover Ratio Statistics
High	Average	Low
12.05	8.61	1.29
(Sep 30 2014)		(Jun 30 2015)

News about Strata Skin Sciences Inc Receivables Turnover Ratios

Strata Skin Sciences’ Stock Stumble A Promising Therapy Clouded by Financial Concerns, refusal null

Behind the Decline: Why Strata Skin Sciences Inc Shares Are Lagging the MarketIn recent days, the shares of Strata Skin Sciences Inc (NASDAQ: SSKN) have found themselves on a downward trajectory, trailing the performance of the broader market despite noteworthy advancements in its technology and promising developments in acne treatment. This paradox raises questions about the underlying factors influencing investor sentiment and market perception of this medical technology company. To provide context for the recent movement in Strata s stock price, it is critical to examine the events that have unfolded around the company and its latest clinical study, which highlights the efficacy of the TheraClearX Acne Therapy System. Published on July 17, the study has garnered attention by demonstrating the device s effectiveness as a treatment option for acne, either as a standalone therapy or in combination with topical medications. The ensuing accolades from medical professionals and potential for enhanced product adoption could suggest a positive trajectory for Strata’s revenue stream. However, the optimism surrounding this breakthrough is tempered by several concerning financial indicators that reflect operational challenges. For instance, Strata recently announced preliminary revenue figures for the second quarter of 2024, estimating earnings between $8 million and $8.4 million. Although these figures may initially appear encouraging, the context is critical; this marks a deterioration in financial performance when compared to previous quarters, triggering a reconsideration of investor expectations.Another significant red flag lies in the company s ability to collect accounts receivable, which has worsened sequentially to 7.17. This number indicates that the average collection period for Strata s receivables has now stretched to 51 days, up from 49 days in the previous quarter. In an industry where receiving timely payments is crucial for sustaining operations and growth, Strata s declining accounts receivable turnover ratio points to a troubling trend that could undermine investor confidence. While in the short term there may be intermittent spikes in interest following announcements regarding new products or clinical successes, the persistent challenges with cash flow highlight potential operational inefficiencies that investors cannot overlook.

SSKN Company Profile • Back to SSKN Efficiency Comparisons • Compare SSKN Receivables Turnover Ratio to its Competitors

Financial Statements
Strata Skin Sciences Inc's Accounts Receivable	$ 4 Millions	Visit SSKN's Balance sheet
Strata Skin Sciences Inc's Sales TTM	$ 29 Millions	Visit SSKN's Income Statement
Sources of SSKN's Revenues		Visit SSKN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SSKN's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SSKN's Growth Rates	SSKN's Roa	SSKN's Inventory Turnover Ratio	SSKN's Dividend Comparisons
SSKN's Profitability Ratios	SSKN's Roi	SSKN's Asset Turnover Ratio	SSKN's Dividend Growth
SSKN's Valuation Ratios	SSKN's Roe	SSKN's Financial Strength Ratios	SSKN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Voyager Therapeutics Inc	19.59	$ 40.374 Millions	$ 2.061 Millions
Sonida Senior Living Inc	19.55	$ 381.141 Millions	$ 19.494 Millions
Siga Technologies Inc	19.47	$ 94.575 Millions	$ 4.856 Millions
Kiniksa Pharmaceuticals International Plc	19.45	$ 677.564 Millions	$ 34.828 Millions
Lipocine Inc	18.38	$ 1.977 Millions	$ 0.108 Millions
Wave Life Sciences Ltd	18.34	$ 59.102 Millions	$ 3.223 Millions
Vystar Corporation	18.31	$ 0.055 Millions	$ 0.003 Millions
Euda Health Holdings Limited	18.26	$ 5.993 Millions	$ 0.328 Millions
Nurix Therapeutics Inc	17.68	$ 83.980 Millions	$ 4.750 Millions
Marpai Inc	16.64	$ 18.099 Millions	$ 1.088 Millions
Bioage Labs Inc	16.01	$ 8.995 Millions	$ 0.562 Millions
Nutriband Inc	15.64	$ 2.037 Millions	$ 0.130 Millions
Plus Therapeutics Inc	15.53	$ 5.213 Millions	$ 0.336 Millions
Talkspace Inc	15.35	$ 228.871 Millions	$ 14.915 Millions
Nanobiotix S a	15.26	$ 36.504 Millions	$ 2.392 Millions
Gsk Plc	15.21	$ 32,667.000 Millions	$ 2,148.000 Millions
Precipio inc	15.02	$ 24.049 Millions	$ 1.601 Millions
Qhslab Inc	14.47	$ 2.692 Millions	$ 0.186 Millions
Arbutus Biopharma Corp	14.04	$ 14.083 Millions	$ 1.003 Millions
Sutro Biopharma Inc	13.92	$ 102.484 Millions	$ 7.365 Millions
Aim Immunotech Inc	13.54	$ 0.088 Millions	$ 0.007 Millions
Amneal Pharmaceuticals Inc	13.44	$ 3,018.308 Millions	$ 224.629 Millions
Rosecliff Acquisition Corp I	13.19	$ 20.547 Millions	$ 1.557 Millions
Xoma Royalty Corporation	13.18	$ 52.149 Millions	$ 3.957 Millions
Nexgel Inc	13.17	$ 10.509 Millions	$ 0.798 Millions
China Pharma Holdings Inc	13.14	$ 4.144 Millions	$ 0.315 Millions
Milestone Scientific Inc	12.98	$ 8.408 Millions	$ 0.648 Millions
Dbv Technologies S a	12.63	$ 5.683 Millions	$ 0.450 Millions
Mannkind Corporation	12.49	$ 348.966 Millions	$ 27.948 Millions
Safe Pro Group Inc	12.46	$ 0.607 Millions	$ 0.049 Millions

Date modified: 2026-08-29T07:54:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.